Use of CpG oligonucleotides in treatment of asthma and allergic disease

Advanced Drug Delivery Reviews

Volumn 61, Issue 3, 2009, Pages 256-262

  Fonseca, David E ^a   Kline, Joel N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Asthma; Atopy; CpG oligonucleotides; Immunotherapy; Inflammation

Indexed keywords

ASTHMA; ATOPY; CPG OLIGONUCLEOTIDES; IMMUNOTHERAPY; INFLAMMATION;

DENDRIMERS; IMMUNOLOGY; NUCLEIC ACIDS; PATHOLOGY;

OLIGONUCLEOTIDES;

AMB A 1 ANTIGEN CPG OLIGODEOXYNUCLEOTIDE CONJUGATE; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE RAGWEED ANTIGEN CONJUGATE; CYTOKINE; DEXAMETHASONE; IMMUNOGLOBULIN E; OVALBUMIN; PLACEBO; RAGWEED ANTIGEN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; ASTHMA; B LYMPHOCYTE; BRONCHUS HYPERREACTIVITY; CLINICAL FEATURE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; ENDOCYTOSIS; EOSINOPHILIA; EXPOSURE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHINOSINUSITIS; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ASTHMA; CPG ISLANDS; CYTOKINES; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOTHERAPY; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS; TH2 CELLS;

EID: 61749093073     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.12.007     Document Type: Review

References (42)

1. Heyman K., Schiller J., and Barnes P. Early Release of Selected Estimates Based on Data from the 2007 National Health Interview Survey, National Center for Health Statistics, June 2008 (2008)
2. Ring J., Kramer U., Schafer T., and Behrendt H. Why are allergies increasing?. Curr. Opin. Immunol. 13 (2001) 701
3. Strachan D.P. Hay fever, hygiene, and household size. Bmj 299 (1989) 1259
4. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., and Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546
5. Krieg A.M. CpG motifs: the active ingredient in bacterial extracts?. Nat. Med. 9 (2003) 831
6. Krieg A.M., and Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol. Rev. 220 (2007) 251
7. Robinson D.S., Hamid Q., Ying S., Tsicopoulos A., Barkans J., Bentley A.M., Corrigan C., Durham S.R., and Kay A.B. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326 (1992) 298
8. Gavett S.H., O'Hearn D.J., Li X., Huang S.K., Finkelman F.D., and Wills-Karp M. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J. Exp. Med. 182 (1995) 1527
9. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2879
10. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., and Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186 (1997) 1623
11. Sur S., Wild J.S., Choudhury B.K., Sur N., Alam R., and Klinman D.M. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J. Immunol. 162 (1999) 6284
12. Kline J.N., Krieg A.M., Waldschmidt T.J., Ballas Z.K., Jain V., and Businga T.R. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J. Allergy. Clin. Immunol. 104 (1999) 1258
13. Kitagaki K., Jain V.V., Businga T.R., Hussain I., and Kline J.N. Immunomodulatory Effects of CpG Oligodeoxynucleotides on Established Th2 Responses. Clin. Diagn. Lab. Immunol. 9 (2002) 1260
14. Jarnicki A.G., Conroy H., Brereton C., Donnelly G., Toomey D., Walsh K., Sweeney C., Leavy O., Fletcher J., Lavelle E.C., Dunne P., and Mills K.H. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J. Immunol. 180 (2008) 3797
15. Peng S.L., Szabo S.J., and Glimcher L.H. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 5545
16. Liu N., Ohnishi N., Ni L., Akira S., and Bacon K.B. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat. Immunol. 4 (2003) 687
17. Chen L., Arora M., Yarlagadda M., Oriss T.B., Krishnamoorthy N., Ray A., and Ray P. Distinct responses of lung and spleen dendritic cells to the TLR9 agonist CpG oligodeoxynucleotide. J. Immunol. 177 (2006) 2373
18. Hartmann G., Weiner G.J., and Krieg A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 9305
19. Kadowaki N., Antonenko S., and Liu Y.J. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c-type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J. Immunol. 166 (2001) 2291
20. Moseman E.A., Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., Liu Y.J., Blazar B.R., and Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+ CD25+ regulatory T cells. J. Immunol. 173 (2004) 4433
21. Mellor A.L., Baban B., Chandler P., Marshall B., Jhaver K., Hansen A., Koni P.A., Iwashima M., and Munn D.H. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171 (2003) 1652
22. Wingender G., Garbi N., Schumak B., Jungerkes F., Endl E., von Bubnoff D., Steitz J., Striegler J., Moldenhauer G., Tuting T., Heit A., Huster K.M., Takikawa O., Akira S., Busch D.H., Wagner H., Hammerling G.J., Knolle P.A., and Limmer A. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36 (2006) 12
23. Hayashi T., Beck L., Rossetto C., Gong X., Takikawa O., Takabayashi K., Broide D.H., Carson D.A., and Raz E. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114 (2004) 270
24. Kline J.N., Waldschmidt T.J., Businga T.R., Lemish J.E., Weinstock J.V., Thorne P.S., and Krieg A.M. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160 (1998) 2555
25. Shirota H., Sano K., Kikuchi T., Tamura G., and Shirato K. Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs. Am. J. Respir. Cell. Mol. Biol. 22 (2000) 176
26. Shirota H., Sano K., Kikuchi T., Tamura G., and Shirato K. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J. Immunol. 164 (2000) 5575
27. Jain V.V., Kitagaki K., Businga T., Hussain I., George C., O'Shaughnessy P., and Kline J.N. CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J. Allergy. Clin. Immunol. 110 (2002) 867
28. Cho J.Y., Miller M., Baek K.J., Han J.W., Nayar J., Rodriguez M., Lee S.Y., McElwain K., McElwain S., Raz E., and Broide D.H. Immunostimulatory DNA inhibits transforming growth factor-beta expression and airway remodeling. Am. J. Respir. Cell. Mol. Biol. 30 (2004) 651
29. Fanucchi M.V., Schelegle E.S., Baker G.L., Evans M.J., McDonald R.J., Gershwin L.J., Raz E., Hyde D.M., Plopper C.G., and Miller L.A. Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys. Am. J. Respir. Crit. Care. Med. 170 (2004) 1153
30. Kline J.N., Kitagaki K., Businga T.R., and Jain V.V. Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am. J. Physiol. Lung Cell Mol. Physiol. 283 (2002) L170
31. Jain V.V., Businga T.R., Kitagaki K., George C.L., O'Shaughnessy P.T., and Kline J.N. Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure. Am. J. Physiol. Lung Cell Mol. Physiol. 285 (2003) L1137
32. Schwartz D.A., Quinn T.J., Thorne P.S., Sayeed S., Yi A.K., and Krieg A.M. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J. Clin. Invest. 100 (1997) 68
33. Kitagaki K., Businga T.R., and Kline J.N. Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice. Clin. Exp. Immunol. 143 (2006) 249
34. Reinero C.R., Cohn L.A., Delgado C., Spinka C.M., Schooley E.K., and Declue A.E. Adjuvanted rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma. Vet. Immunol. Immunopathol. 121 (2008) 241
35. Hussain I., Jain V.V., Kitagaki K., Businga T.R., O'Shaughnessy P., and Kline J.N. Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides. Laryngoscope 112 (2002) 1819
36. Rhee C.S., Libet L., Chisholm D., Takabayashi K., Baird S., Bigby T.D., Lee C.H., Horner A.A., and Raz E. Allergen-independent immunostimulatory sequence oligodeoxynucleotide therapy attenuates experimental allergic rhinitis. Immunology 113 (2004) 106
37. Suzuki M., Matsumoto T., Ohta N., Min W.P., and Murakami S. Intranasal CpG DNA therapy during allergen exposure in allergic rhinitis. Otolaryngol. Head Neck Surg. 136 (2007) 246
38. Magone M.T., Chan C.C., Beck L., Whitcup S.M., and Raz E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur. J. Immunol. 30 (2000) 1841
39. Simons F.E., Shikishima Y., Van Nest G., Eiden J.J., and HayGlass K.T. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy. Clin. Immunol. 113 (2004) 1144
40. Tulic M.K., Fiset P.O., Christodoulopoulos P., Vaillancourt P., Desrosiers M., Lavigne F., Eiden J., and Hamid Q. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy. Clin. Immunol. 113 (2004) 235
41. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., Li H., Coffman R., Seyfert V., Eiden J.J., and Broide D. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355 (2006) 1445
42. Gauvreau G.M., Hessel E.M., Boulet L.P., Coffman R.L., and O'Byrne P.M. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am. J. Respir. Crit. Care. Med. 174 (2006) 15